Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1980 May;17(5):865–870. doi: 10.1128/aac.17.5.865

Plaque inhibition assay for drug susceptibility testing of influenza viruses.

F G Hayden, K M Cote, R G Douglas Jr
PMCID: PMC283889  PMID: 7396473

Abstract

The relative antiviral activities of four drugs against contemporary strains of influenza A and B viruses were determined in Madin-Darby canine kidney cell monolayers with a plaque inhibition assay. This assay proved to be a reliable, rapid method of determining 50% inhibitory concentrations that correlated well with clinically achievable drug levels and the results of clinical trials. Contemporary strains of influenza A viruses (subtypes H1N1, H3N2, HSW1N1) required amantadine hydrochloride and rimantadine hydrochloride 50% inhibitory concentrations in the range of 0.2 to 0.4 microgram/ml, whereas 50% inhibitory concentrations ranged from approximately 50 to 100 micrograms/ml against influenza B viruses. Ribavirin was approximately 10-fold less active than amantadine hydrochloride against influenza A viruses, and the ribavirin 50% inhibitory concentrations against both influenza A and B viruses ranged from 2.6 to 6.8 micrograms/ml. Inosiplex had no antiviral activity in this test system.

Full text

PDF
867

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aoki F. Y., Sitar D. S., Ogilvie R. I. Amantadine kinetics in healthy young subjects after long-term dosing. Clin Pharmacol Ther. 1979 Dec;26(6):729–736. doi: 10.1002/cpt1979266729. [DOI] [PubMed] [Google Scholar]
  2. Appleyard G. Amantadine-resistance as a genetic marker for influenza viruses. J Gen Virol. 1977 Aug;36(2):249–255. doi: 10.1099/0022-1317-36-2-249. [DOI] [PubMed] [Google Scholar]
  3. Appleyard G., Maber H. B. A plaque assay for the study of influenza virus inhibitors. J Antimicrob Chemother. 1975 Dec;1(4 Suppl):49–53. doi: 10.1093/jac/1.suppl_4.49. [DOI] [PubMed] [Google Scholar]
  4. Bleidner W. E., Harmon J. B., Hewes W. E., Lynes T. E., Hermann E. C. Absorption, distribution and excretion of amantadine hydrochloride. J Pharmacol Exp Ther. 1965 Dec;150(3):484–490. [PubMed] [Google Scholar]
  5. Chang T. W., Weinstein L. Antiviral activity of isoprinosine in vitro and in vivo. Am J Med Sci. 1973 Feb;265(2):143–146. doi: 10.1097/00000441-197302000-00005. [DOI] [PubMed] [Google Scholar]
  6. Cochran K. W., Maassab H. F., Tsunoda A., Berlin B. S. Studies on the antiviral activity of amantadine hydrochloride. Ann N Y Acad Sci. 1965 Jul 30;130(1):432–439. doi: 10.1111/j.1749-6632.1965.tb12579.x. [DOI] [PubMed] [Google Scholar]
  7. Cohen A., Togo Y., Khakoo R., Waldman R., Sigel M. Comparative clinical and laboratory evaluation of the prophylactic capacity of ribavirin, amantadine hydrochloride, and placebo in induced human influenza type A. J Infect Dis. 1976 Jun;133 (Suppl):A114–A120. doi: 10.1093/infdis/133.supplement_2.a114. [DOI] [PubMed] [Google Scholar]
  8. GRUNERT R. R., MCGAHEN J. W., DAVIES W. L. THE IN VIVO ANTIVIRAL ACTIVITY OF 1-ADAMANTANAMINE (AMANTADINE). I. PROPHYLACTIC AND THERAPEUTIC ACTIVITY AGAINST INFLUENZA VIRUSES. Virology. 1965 Jun;26:262–269. doi: 10.1016/0042-6822(65)90273-4. [DOI] [PubMed] [Google Scholar]
  9. Ginsberg T., Glasky A. J. Inosiplex: an immunomodulation model for the treatment of viral disease. Ann N Y Acad Sci. 1977 Mar 4;284:128–138. doi: 10.1111/j.1749-6632.1977.tb21944.x. [DOI] [PubMed] [Google Scholar]
  10. Glasgow L. A., Galasso G. J. Isoprinosine: lack of antiviral activity in experimental model infections. J Infect Dis. 1972 Aug;126(2):162–169. doi: 10.1093/infdis/126.2.162. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Greenblatt D. J., DiMascio A., Harmatz J. S., Bernardo D. L., Marder J. E. Pharmacokinetics and clinical effects of amantadine in drug-induced extrapyramidal symptoms. J Clin Pharmacol. 1977 Nov-Dec;17(11-12):704–708. doi: 10.1002/j.1552-4604.1977.tb01545.x. [DOI] [PubMed] [Google Scholar]
  12. Grunert R. R., Hoffmann C. E. Sensitivity of influenza A/New Jersey/8/76 (Hsw1N1) virus to amantadine-HCl. J Infect Dis. 1977 Aug;136(2):297–300. doi: 10.1093/infdis/136.2.297. [DOI] [PubMed] [Google Scholar]
  13. Hadden J. W., Hadden E. M., Coffey R. G. Isoprinosine augmentation of phytohemagglutinin-induced lymphocyte proliferation. Infect Immun. 1976 Feb;13(2):382–387. doi: 10.1128/iai.13.2.382-387.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Halsted C. C., Minnefor A. B., Lietman P. S. Inhibition of cytomegalovirus by rifampin. J Infect Dis. 1972 May;125(5):552–555. doi: 10.1093/infdis/125.5.552. [DOI] [PubMed] [Google Scholar]
  15. Huffman J. H., Sidwell R. W., Khare G. P., Witkowski J. T., Allen L. B., Robins R. K. In vitro effect of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (virazole, ICN 1229) on deoxyribonucleic acid and ribonucleic acid viruses. Antimicrob Agents Chemother. 1973 Feb;3(2):235–241. doi: 10.1128/aac.3.2.235. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Kremzner L. T., Harter D. H. Antiviral activity of oxidized polyamines and aldehydes. Biochem Pharmacol. 1970 Sep;19(9):2541–2550. doi: 10.1016/0006-2952(70)90002-x. [DOI] [PubMed] [Google Scholar]
  17. Longley S., Dunning R. L., Waldman R. H. Effect of isoprinosine against challenge with A(H3N2)-Hong Kong influenza virus in volunteers. Antimicrob Agents Chemother. 1973 Apr;3(4):506–509. doi: 10.1128/aac.3.4.506. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Lubeck M. D., Schulman J. L., Palese P. Susceptibility of influenza A viruses to amantadine is influenced by the gene coding for M protein. J Virol. 1978 Dec;28(3):710–716. doi: 10.1128/jvi.28.3.710-716.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Magnussen C. R., Douglas R. G., Jr, Betts R. F., Roth F. K., Meagher M. P. Double-blind evaluation of oral ribavirin (Virazole) in experimental influenza A virus infection in volunteers. Antimicrob Agents Chemother. 1977 Oct;12(4):498–502. doi: 10.1128/aac.12.4.498. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Monto A. S., Gunn R. A., Bandyk M. G., King C. L. Prevention of Russian influenza by amantadine. JAMA. 1979 Mar 9;241(10):1003–1007. [PubMed] [Google Scholar]
  21. Muldoon R. L., Mezny L., Jackson G. G. Effect of isoprinosine against influenza and some other viruses causing respiratory diseases. Antimicrob Agents Chemother. 1972 Sep;2(3):224–228. doi: 10.1128/aac.2.3.224. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Oxford J. S. Inhibition of the replication of influenza A and B viruses by a nucleoside analogue (ribavirin). J Gen Virol. 1975 Sep;28(3):409–414. doi: 10.1099/0022-1317-28-3-409. [DOI] [PubMed] [Google Scholar]
  23. Oxford J. S., Potter C. W. Aminoadamantane-resistant strains of influenza A2 virus. J Hyg (Lond) 1973 Jun;71(2):227–236. doi: 10.1017/s0022172400022701. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Schild G. C., Sutton R. N. Inhibition of influenza viruses in vitro and in vivo by 1-adamantanamine hydrochloride. Br J Exp Pathol. 1965 Jun;46(3):263–273. [PMC free article] [PubMed] [Google Scholar]
  25. Skehel J. J., Hay A. J., Armstrong J. A. On the mechanism of inhibition of influenza virus replication by amantadine hydrochloride. J Gen Virol. 1978 Jan;38(1):97–110. doi: 10.1099/0022-1317-38-1-97. [DOI] [PubMed] [Google Scholar]
  26. Smith G. B., Purcell R. H., Chanock R. M. Effect of amantadine hydrochloride on parainfluenza type 1 virus infections in adult volunteers. Am Rev Respir Dis. 1967 Apr;95(4):689–690. doi: 10.1164/arrd.1967.95.4.689. [DOI] [PubMed] [Google Scholar]
  27. Smorodintsev A. A., Zlydnikov D. M., Kiseleva A. M., Romanov J. A., Kazantsev A. P., Rumovsky V. I. Evaluation of amantadine in artificially induced A2 and B influenza. JAMA. 1970 Aug 31;213(9):1448–1454. [PubMed] [Google Scholar]
  28. Subak-Sharpe J. H., Timbury M. C., Williams J. F. Rifampicin inhibits the growth of some mammalian viruses. Nature. 1969 Apr 26;222(5191):341–345. doi: 10.1038/222341a0. [DOI] [PubMed] [Google Scholar]
  29. Tisdale M., Bauer D. J. A comparison of test methods in influenza chemotherapy. J Antimicrob Chemother. 1975 Dec;1(4 Suppl):55–62. doi: 10.1093/jac/1.suppl_4.55. [DOI] [PubMed] [Google Scholar]
  30. Tisdale M., Bauer D. J. The relative potencies of anti-influenza compounds. Ann N Y Acad Sci. 1977 Mar 4;284:254–263. doi: 10.1111/j.1749-6632.1977.tb21958.x. [DOI] [PubMed] [Google Scholar]
  31. Tobita K., Sugiura A., Enomote C., Furuyama M. Plaque assay and primary isolation of influenza A viruses in an established line of canine kidney cells (MDCK) in the presence of trypsin. Med Microbiol Immunol. 1975 Dec 30;162(1):9–14. doi: 10.1007/BF02123572. [DOI] [PubMed] [Google Scholar]
  32. Togo Y. In vitro effect of virazole against influenza viruses. Antimicrob Agents Chemother. 1973 Dec;4(6):641–642. doi: 10.1128/aac.4.6.641. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Togo Y., McCracken E. A. Double-blind clinical assessment of ribavirin (virazole) in the prevention of induced infection with type B influenza virus. J Infect Dis. 1976 Jun;133 (Suppl):A109–A113. doi: 10.1093/infdis/133.supplement_2.a109. [DOI] [PubMed] [Google Scholar]
  34. Wingfield W. L., Pollack D., Grunert R. R. Therapeutic efficacy of amantadine HCl and rimantadine HCl in naturally occurring influenza A2 respiratory illness in man. N Engl J Med. 1969 Sep 11;281(11):579–584. doi: 10.1056/NEJM196909112811102. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES